ACS updates guideline for cervical cancer screening

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.

The guideline appears in CA: A Cancer Journal for Clinicians.

The updated guideline recommends that individuals with a cervix initiate cervical cancer screening at age 25, continuing through age 65, and that primary human papillomavirus testing every 5 years be the preferred method of testing.

The guideline says using HPV testing in combination with a Pap test (called cotesting) every five years or Pap tests alone every three years are acceptable options for now, as not all labs have transitioned to primary HPV testing.

“These streamlined recommendations can improve compliance and reduce potential harms,” Debbie Saslow, managing director of HPV & GYN Cancers for ACS, said in a statement. “They are made possible by some important developments that have allowed us to transform our approach to cervical cancer screening, primarily a deeper understanding of the role of HPV and the development of tools to address it.”

Virtually all cases of cervical cancer are caused by infection with high-risk strains of HPV. Evidence shows the HPV test is more accurate than the Pap test and can be done less often; one HPV test every five years is more effective than a Pap test every three years, and even every year as was recommended in the 1980’s and 1990’s, in reducing the risk of cervical cancer.

A negative HPV test is linked to a very low cervical cancer risk. In addition, a vaccine for HPV has been in use for nearly 15 years, and more women of screening age are now vaccinated and protected from the majority of cervical cancers.

The previous ACS guideline, released in 2012, called for screening starting at age 21. Since then, HPV vaccination rates have improved in the United States. Data suggest vaccination has led to a drop in rates of precancerous cervical changes, the precursors to cancer. In addition, cervical cancer incidence is low in this age group. Cancer registry data from 2011 to 2015 indicates an estimated 108 cases of invasive cervical cancer in women 20 to 24 years in the U.S. each year, a number that is expected to continue to fall as vaccine use increases.

There are also potential harms related to the treatment of precancerous cells identified by screening including preterm birth, and screening has not been shown to lower the rate of cancer in women in this age group. Also, most HPV infections in women in this age group become undetectable in 1-2 years. Those factors led the ACS to move the recommended age to initiate cervical cancer screening to 25.

“We estimate that compared with the currently recommended strategy of cytology (Pap testing) alone beginning at age 21 and switching to co-testing at age 30 years, starting with primary HPV testing at age 25 will prevent 13% more cervical cancers and 7% more cervical cancer deaths,” Saslow said. “Our model showed we could do that with a 9% increase in follow-up procedures, but with 45% fewer tests required overall.”

Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login